COVID-19 Operational Impact Update

June 16, 2020
Cautionary Statement

This presentation includes “forward-looking statements.” These statements relate to future events, including, but not limited to, statements regarding our liquidity, operating results, future earnings, financial position, operational and strategic initiatives, and developments in legislation, regulation, and the healthcare industry more generally. These forward-looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are uncertain, particularly with regard to developments related to COVID-19. Actual results, performance or achievements could differ materially from those expressed in any forward-looking statement.

Examples of uncertainties that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements include, but are not limited to, developments related to COVID-19 and the factors described under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

We assume no obligation to update any forward-looking statements or information subsequent to the dates such statements are made. Investors are cautioned not to place undue reliance on our forward-looking statements.
Today’s Discussion

- Recap of Year-to-Date (YTD) 2020
- Update on Volumes
- Update on Liquidity
- Summary
- Q&A Session
Recap of YTD 2020

• Outperformance (January through mid-March)
  ✓ All business segments performed at or above expectations
  ✓ 2019 operational changes drove results with pathway for continued improvement
  ✓ Commenced early preparations for COVID-19 impact

• COVID-19 Response and Impact (Mid-March through early May)
  ✓ Although our facilities were not overwhelmed, COVID-19 confirmed cases and PUIs escalated rapidly; we focused on patient and staff protection and ensuring we had adequate PPE supplies
  ✓ Significant, rapid volume declines driven by shelter-in-place orders and mandated suspension of nearly all elective procedures
  ✓ Continued to actively and responsibly manage costs while maintaining quality of care
  ✓ Financial guidance withdrawn on April 2nd due to uncertainty related to COVID-19
  ✓ Proactive steps taken to preserve and enhance liquidity
  ✓ Began receiving federal stimulus aid
Recap of YTD 2020, continued

- **COVID-Safe Recovery and Reopening (Mid-May to Mid-June)**
  - Coordination of comprehensive recovery effort; continuity of safety prioritized
    - PPE inventory secured with reliable suppliers
    - In-house COVID-19 testing in all markets
    - Coordinating with physicians and patients to schedule procedures
    - Through targeted marketing and communications, reassuring public that our facilities are safe and accessible with strict protocols in place
  - Volumes beginning to recover, but not yet at pre-COVID levels
  - Safe reopening of our surgery centers
  - Executed on additional liquidity enhancements; receipt of additional federal stimulus aid

- **Plans to Address Potential Future Surge of COVID-19**
  - Protect patients and staff; preserve cleanliness and safety of facilities
  - Ensure sufficient patient care capacity, staffing and PPE
  - Isolate patients to single facility or wing/area, where possible
  - Designate access for potential COVID-19 patients
  - Transparency in communications and reporting
## 2020 Volume Statistics

### Initial Outperformance vs. Initial COVID Impact

*Percent Change from Prior Year*

<table>
<thead>
<tr>
<th>Volume Statistics (a)</th>
<th>YTD February</th>
<th>March – full month</th>
<th>2H March</th>
<th>April</th>
<th>May</th>
<th>1H June</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admissions</td>
<td>1.1%</td>
<td>(15.2%)</td>
<td>(~25%)</td>
<td>(~33%)</td>
<td>~80%</td>
<td>~90%</td>
</tr>
<tr>
<td>OP visits</td>
<td>5.5%</td>
<td>(22.3%)</td>
<td>(~35%)</td>
<td>(~61%)</td>
<td>~60%</td>
<td>~70%</td>
</tr>
<tr>
<td>ER visits</td>
<td>6.0%</td>
<td>(16.2%)</td>
<td>(~27%)</td>
<td>(~48%)</td>
<td>~65%</td>
<td>~75%</td>
</tr>
<tr>
<td>Hospital surgeries</td>
<td>0.4%</td>
<td>(21.1%)</td>
<td>(~38%)</td>
<td>(~55%)</td>
<td>~80%</td>
<td>~95%</td>
</tr>
<tr>
<td>USPI surgical cases</td>
<td>2.0%</td>
<td>(28.6%)</td>
<td>(~53%)</td>
<td>(~80%)</td>
<td>~70%</td>
<td>~85%</td>
</tr>
</tbody>
</table>

### Recovery

*Percent of pre-COVID Levels (b)*

(a) Same-hospital basis for hospital statistics; USPI surgical cases are on a same-facility system-wide basis
(b) Same-business-day basis
Liquidity Update

• **Currently have sufficient cash resources and available liquidity under our line-of-credit facility**

• **As of Monday, June 15th, we had approximately $2.665 billion of excess cash on hand and no borrowings outstanding under our $1.9 billion line of credit facility**
  - ~$1.5 billion of Medicare advances we have received has to be repaid to the government by early April 2021

• **Steps taken proactively during Q2’20 to enhance liquidity:**
  - Amended our line-of-credit facility to increase the borrowing capacity from $1.5 billion to $1.9 billion; $500 million of outstanding line-of-credit borrowings as of March 31, 2020 were repaid in April
  - Two separate offerings of Secured Notes – $600 million of 4.625% Notes issued in June and $700 million of 7.5% Notes issued in April
  - $300 million reduction (~40%) in planned CAPEX spending in 2020
  - Application for and receipt of federal stimulus grant monies; these grants will be recognized as revenue once criteria associated with such grants are met (e.g., grant funds will be recognized as revenue each quarter by facility up to the amount of that facility’s lost revenues and additional costs due to COVID-19)
    - We received ~$172 million of additional grant monies on June 12th for safety net hospitals; to date, we’ve received ~$689 million of grant aid earmarked for healthcare providers from stimulus legislation, including the CARES Act.

• **Additional liquidity enhancements or opportunities:**
  - Anticipated proceeds from the sale of our Memphis hospitals in 2020 (~$350 million)
  - Other CARES Act provisions (e.g., postponement of Medicaid DSH revenue reductions of ~$60m that does not need to be repaid, elimination of the Medicare-related 2% sequestration revenue reduction for the remainder of 2020 of ~$67m that does not need to be repaid, deferral of the company payroll tax match for remainder of 2020 of ~$250m – 50% has to be repaid in Dec. 2021 and 50% in Dec. 2022)
  - Potential sale leaseback of non-strategic medical office buildings
Summary

• Pre-COVID-19 performance continued strong momentum from 2019

• Responded to fluid environment to address operational challenges associated with COVID-19 and prioritized safety

• Executing an effective and safe restart with detailed planning and measures

• Bolstered balance sheet; efforts to enhance liquidity have strengthened financial position in uncertain times

• Appreciative of stimulus aid received so far, which will offset some of the pandemic impact

• Ongoing operational turnaround and discipline begun in 2018 and 2019 has been instrumental in addressing the COVID impact

• Well prepared for spike in COVID demand if that occurs; continuing to provide quality, safe care for all patients
Questions and Answers

Ron Rittenmeyer
Executive Chairman and CEO

Saum Sutaria
President and COO

Dan Cancelmi
EVP and Chief Financial Officer